Yu Jiang

Yu Jiang

Auto-generated profile, based on publicly available information

Yu Jiang

The Cardiac Arrhythmia Center, National Clinical Research Center of Cardiovascular Diseases, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
YJYu Jiang
Yu Jiang
MYMiao Yu
Miao Yu
ZSZhi-Feng Song
Zhi-Feng Song
ZWZhi-Yao Wei
Zhi-Yao Wei
JHJi Huang
Ji Huang
HQHaiyan Qian
Haiyan Qian
Purpose: Accumulating evidence indicates that mesenchymal stem cells (MSCs)-derived exosomes hold significant potential for the treatment of atherosclerosis. However, large-scale production and organ-specific targeting of exosomes are still challenges for further clinical applications. This study aims to explore the targeted efficiency and therapeutic potential of biomimetic platelet membrane-coated exosome-mimetic nanovesicles (P-ENVs) in atherosclerosis. Methods: To produce exosome-mimetic nanovesicles (ENVs), MSCs were successively extruded through polycarbonate porous membranes. P-ENVs were engineered by fusing MSC-derived ENVs with platelet membranes and characterized using transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and Western blot. The stability and safety of P-ENVs were also assessed. The targeted efficacy of P-ENVs was evaluated using an in vivo imaging system (IVIS) spectrum imaging system and immunofluorescence. Histological analyses, Oil Red O (ORO) staining, and Western blot were used to investigate the anti-atherosclerotic effectiveness of P-ENVs. Results: Both ENVs and P-ENVs exhibited similar characteristics to exosomes. Subsequent miRNA sequencing of P-ENVs revealed their potential to mitigate atherosclerosis by influencing biological processes related to cholesterol metabolism. In an ApoE−/− mice model, the intravenous administration of P-ENVs exhibited enhanced targeting of atherosclerotic plaques, resulting in a significant reduction in lipid deposition and necrotic core area. Our in vitro experiments showed that P-ENVs promoted cholesterol efflux and reduced total cholesterol content in foam cells. Further analysis revealed that P-ENVs attenuated intracellular cholesterol accumulation by upregulating the expression of the critical cholesterol transporters ABCA1 and ABCG1. Conclusion: This study highlighted the potential of P-ENVs as a novel nano-drug delivery platform for enhancing drug delivery efficiency while concurrently mitigating adverse reactions in atherosclerotic therapy.

30 August 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
ZSZhiFeng Song
ZhiFeng Song
CDChilie Danzeng
Chilie Danzeng
YJYu Jiang
Yu Jiang
JYJingang Yang
Jingang Yang
WYWeixian Yang
Weixian Yang
YYYuejin Yang
Yuejin Yang
Background: Globally, acute myocardial infarction (AMI) is among the primary causes of mortality. The ideal approach for blood pressure (BP) management for patients experiencing ST-segment elevation myocardial infarction (STEMI) who receive percutaneous coronary intervention (PCI) remains a topic of ongoing debate. Current guidelines on BP management lack specific recommendations for STEMI patients undergoing PCI, resulting in substantial individual variability and uncertainties in clinical treatment strategies. This research seeks to determine the ideal BP levels linked to the lowest risk of in-hospital mortality and long-term adverse endpoints in STEMI patients receiving PCI. Methods: This retrospective study analyzed data from the China Acute Myocardial Infarction (CAMI) Registry, enrolling 10,482 STEMI patients undergoing PCI at 108 Chinese hospitals from January 2013 to September 2014. The primary outcome was in-hospital mortality. Secondary outcomes included 2-year all-cause mortality, severe bleeding, and major adverse cardiac and cerebrovascular events (MACCEs), defined as a combination of all-cause mortality, myocardial infarction (MI), or stroke. The analysis of the relationship between admission systolic blood pressure (SBP)/diastolic blood pressure (DBP) and the primary and secondary outcomes as continuous and categorical variables was conducted using restricted cubic spline (RCS) analysis and Cox regression models. Results: RCS analysis revealed that a J-shaped association existed between admission SBP/DBP and the risk of the primary outcome, with significant nonlinearity (both p < 0.001). Both lower and higher SBP/DBP levels were linked to an elevated risk of in-hospital mortality. The ideal SBP/DBP levels to minimize the in-hospital mortality risk were 157/94 mmHg. Compared to the reference SBP/DBP group (120–129/70–79 mmHg), lower admission SBP (<109 mmHg) or DBP (60–69 mmHg) significantly elevated the risk of the primary outcome. The adjusted hazard ratio (HR) for SBP levels of 100–109 mmHg and <100 mmHg was 1.08 (95% confidence interval (CI): 1.00–1.17; p = 0.0395 and p = 0.043, respectively), and for DBP of 60–69 mmHg, the adjusted HR was 1.07 (95% CI: 1.01–1.14, p = 0.0305). Similarly, the J-shaped curve was also noted between SBP/DBP and secondary outcomes, such as all-cause mortality, severe bleeding and MACCEs. However, no significant non–linear relationship was observed between SBP/DBP and recurrent MI at 2-year follow-up. Conclusions: Among STEMI patients undergoing PCI, a J-curve relationship in in-hospital mortality was observed with a nadir at 157/94 mmHg. Similar J-shaped trends were also observed for secondary outcomes including all-cause mortality, severe bleeding and MACCEs. However, no significant nonlinear correlation was found between admission BP and recurrent MI within 2 years. Clinical Trial Registration: NCT01874691, https://www.clinicaltrials.gov/study/NCT01874691?term=NCT01874691&rank=1.

1 January 2026 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
FTFangshun Tan
Fangshun Tan
YJYu Jiang
Yu Jiang
RWRuizhi Wang
Ruizhi Wang
ZHZiquan Hu
Ziquan Hu
YXYuting Xia
Yuting Xia
WYWeixian Yang
Weixian Yang
Background: Psoriasis (PSO) and atherosclerosis (AS) are chronic inflammatory diseases that frequently coexist, with each condition exacerbating the other. However, the underlying mechanisms remain poorly understood, partly due to the lack of a suitable animal model that recapitulates this bidirectional comorbidity. Methods: PSO‐AS mouse models were constructed by combining high‐fat diet (HFD)–induced AS with imiquimod (IMQ)‐triggered psoriatic inflammation in ApoE −/− mice. PSO severity was assessed via skin manifestation, hematoxylin and eosin (H&E) staining, PSO area and severity index (PASI) score, quantitative real‐time PCR (qRT‐PCR), and serum ELISA, while AS was assessed by en face Oil red O (ORO) staining of aorta, H&E staining, ORO staining, Sirius Red (SR) staining, and immunofluorescence (IF) staining of the aortic root section. Mechanistic insights were obtained via proteomics, machine learning (ML), and validation of macrophage polarization in both skin and plaques. Results: Chronic PSO model more closely resembles real‐world conditions than acute PSO model. Combining the IMQ application with a HFD, both the PSO‐AS group and the PSO group developed obvious psoriatic skin lesion, but the PSO‐AS group showed the highest epidermal thickness, PASI scores, and expression levels of psoriatic biomarkers (Interleukin‐17A [IL‐17A] and Interleukin‐23 [IL‐23]) and inflammatory factors (e.g., tumor necrosis factor alpha [TNF‐α] and Interleukin‐6 [IL‐6]), implying that AS may exacerbate PSO. Similarly, the PSO‐AS and AS groups both developed obvious plaque in the aorta, while the PSO‐AS group has the largest plaque area, necrotic core (NC) area, lipid content with the least fibrous cap (FC) thickness, and collagen content, illustrating that PSO conspicuously aggravated AS progression and led to an unstable plaque shift. Statistical analysis also confirms that PSO and AS mutually exacerbate each other, forming a vicious cycle that may be strongly associated with IL‐17. Proteomics and ML revealed marked M1 macrophage polarization in PSO‐AS mice. Validation by Western blot and IF showed upregulated M1 markers (CD86) and downregulated M2 markers (CD163) in both skin lesions and aortic roots, indicating that M1‐skewed macrophages fuel the vicious cycle. Besides, we explore that IFIT3 may serve as a promising biomarker for M1 macrophages in PSO‐AS skin. Conclusions: This novel PSO‐AS mouse model faithfully recapitulates the bidirectional exacerbation seen clinically and uncovers M1 macrophage polarization as a key driver of this comorbidity. The model provides a robust platform for mechanistic and therapeutic studies of PSO‐associated cardiovascular disease (CVD).

20 October 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
SWSixian Weng
Sixian Weng
JPJianqiu Pei
Jianqiu Pei
HLHui Li
Hui Li
SCSijing Cheng
Sijing Cheng
HHHao Huang
Hao Huang
WHWei Hua
Wei Hua
Background: Left bundle branch area pacing may reduce new‐onset atrial fibrillation. However, its mechanism and the comparison of atrial reverse remodeling effect between left bundle branch pacing (LBBP) and left ventricular septal pacing (LVSP) has not been elucidated. We aim to investigate reverse atrial remodeling by LBBP and LVSP in a canine model of rapid pacing‐induced dyssynchronous heart failure (DHF). Methods: Twenty‐six beagles followed a 6‐week protocol: controls (n=4), rapid atrial pacing (n=4), DHF (n=6), DHF+LBBP and DHF+LVSP (3 weeks DHF followed by 3 weeks LBBP or LVSP, both n=6). Atrial emptying fraction, functional, and electrophysiological parameters were dynamically assessed. Atrial fibrosis was analyzed in tissue samples. Results: Within 3 weeks DHF increased atrial volumes and diminished RA and LA emptying fraction and strains significantly compared with baseline. Subsequent 3 weeks of LBBP increased emptying fraction and strains significantly. At week 6, P‐wave duration was shorter in DHF+LBBP than in DHF. Atrial fibrillation was only inducible in DHF animals. Left atrial appendage levels of collagen I/III and α‐SMA deposition and fibrosis were lower in DHF+LBBP compared with DHF animals. LBBP reversed atrial structural and electrical parameters to the levels in rapid atrial pacing animals. LVSP improved those parameters compared with those in DHF but did not normalize them to the levels in the rapid atrial pacing animals. Conclusions: LBBP significantly reverses DHF‐induced functional, cellular, and molecular remodeling in the atria, while a smaller amelioration is achieved with LVSP. The findings may explain the reduction in new‐onset atrial fibrillation after LBBP.